FDA Approves Regeneron's Livsayis for Generalized Myasthenia Gravis
11/19/2026
Impact: 75
Healthcare
The FDA approved Regeneron Pharmaceuticals’ Livsayis (cemdisiran) for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies. The C5-directed siRNA therapy is injected subcutaneously four times a year, a dosing frequency the company says is unique among gMG treatments, and approval was supported by Phase 3 NIMBLE trial results showing rapid, sustained disease control. Livsayis is Regeneron’s first approved siRNA therapy and its first neurology medicine; the article reports no financial figures or stock-price impact.
AI summary, not financial advice
Share: